The High Expression of Legumain in Canine Neoplasms: A Retrospective Analysis of 100 Cases
Open Access
Abstract
Legumain, a novel asparaginyl endopeptidase, has been observed to be overexpressed in several types of human solid tumors. Elevated levels of legumain are found in human cancers, and this oncoprotein may facilitate tumor invasion and metastasis when overexpressed. These findings suggest that legumain plays a malignant role in cancer biology. However, currently, no publications have identified the role of legumain in the development of canine cancers. The present study first compared the expression patterns of legumain in paraffin-embedded canine tumor tissues, with those of normal tissues, by immunohistochemistry. A total of 100 canine tumor samples, including mast cell tumors, soft tissue sarcoma, hemangiosarcoma, lymphoma, mammary gland carcinoma, hepatoid gland tumor, squamous cell carcinoma, trichoblastoma, and melanoma were evaluated. Compared with the normal tissues, all tumor samples displayed high intensities of legumain expression. Mesenchymal-type tumors displayed immunoreactivity for legumain, with an average expression of 40.07% ± 1.70%, which was significantly lower than those of epithelial tumors and other types of tumors, which had median expressions of 49.12% ± 1.75% and 47.35% ± 2.71%, respectively (p < 0.05). These findings indicate that legumain has a high potential to be a candidate for distinguishing tumors from normal tissues. Although further studies on a larger number of cases are necessary to clarify the clinical application of legumain, the overexpression patterns of legumain in canine tumor tissues are reported, for the first time, in this study.Keywords
Funding Information
- Council of Agriculture in Taiwan (110AS-10.1.7-AD-U1)
- VGHUST Joint Research Program (111-G6-2-2)
This publication has 32 references indexed in Scilit:
- Expression of Legumain Correlates with Prognosis and Metastasis in Gastric CarcinomaPLOS ONE, 2013
- The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell InvasionPLOS ONE, 2012
- Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicityNanomedicine: Nanotechnology, Biology and Medicine, 2011
- A Mesoderm-Derived Precursor for Mesenchymal Stem and Endothelial CellsCell Stem Cell, 2010
- Legumain expression as a prognostic factor in breast cancer patientsBreast Cancer Research and Treatment, 2006
- Targeting tumor-associated macrophages as a novel strategy against breast cancerJournal of Clinical Investigation, 2006
- Legumain Expression in Relation to Clinicopathologic and Biological Variables in Colorectal CancerClinical Cancer Research, 2005
- A Dog's Breakfast?Science, 2003
- The MEROPS Database as a Protease Information SystemJournal of Structural Biology, 2001
- ENVIRONMENTAL CAUSES FOR SINONASAL CANCERS IN PET DOGS, AND THEIR USEFULNESS AS SENTINELS OF INDOOR CANCER RISKJournal of Toxicology and Environmental Health, Part A, 1998